

PHARMACOPOEIAL REVIEW & HARMONISATION A STRATEGY FOR MULTICOMPENDIAL COMPLIANCE SO WHAT?

Why action is necessary?

- Excipients makers & users continue to be CHALLENGED BY NON VALUE-ADDED TESTING to ensure regulatory compliance.
- Pharmacopoeial harmonisation has not achieved its goals as even more compendia publish DIVERGENT MONOGRAPHS.

Where are we now?

Companies have INTERNAL PROCEDURES TO CROSS-VALIDATE PHARMACOPOEIAL STANDARDS which some pharmacopoeias have accepted but there is NO STANDARDISED INDUSTRY APPROACH.

What do we need?

- **7** Our industry NEEDS A BEST PRACTICE which enables companies to align their internal procedures achieving compliance with multiple compendia.
- **▶** Such an approach will NEED TO BE ACCEPTED BY REGULATORY AUTHORITIES.

How do we get there?

- **J** Understand the regulatory framework to **DEVELOP A STATEMENT OF INTENT** for a best practice
- **TREATE A TASK FORCE** to deliver a best practice, composed of members who are:
 - Knowledgeable of method development and validation;
 - Experienced in compendial matters;
 - · Have a breadth of understanding of analytical techniques.

What's in it for you?

- **7** The opportunity to DESIGN AN INDUSTRY STANDARD.
- **EXCHANGING AND BENCHMARKING on industry approaches with KEY STAKEHOLDERS.**
- **5** ENGAGING WITH COMPENDIA AND IPEC SISTER ASSOCIATIONS to align with our proposal.

What's expected of you?

- Two face-to-face meetings.
- 7 Teleconferences as needed.

What's the proposed timeline?

- Launch the TASK FORCE IN OCTOBER 2019.
- **J** BEST PRACTICE deliverable date in MARCH 2021.

Interested?

Contact the IE Secretariat (info@ipec-europe.org) by 31 August.